You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
線下調研 | Tenbagger系列調研之創新型醫療器械公司先健科技(1302.HK)
格隆匯 11-24 19:59

作者 | 格隆匯小編

數據支持 | 勾股大數據

在醫改政策密集性出台之下,創新藥成為其繼續存活下去的唯一出路,創新藥已經進入下半場的“決賽圈”,而對於醫療器械而言,創新醫療器械剛剛進入上半場的“初賽局”。

2020年11月24日,先健科技公司(1302.HK)獲悉,高瓴資本和德福資本近日通過場內大宗交易受讓中央匯金投資有限責任公司(中國光大控股有限公司的母公司)(以下稱“光大控股”)於交易當天持有的先健科技全部股權。作為業內領先的投資機構,高瓴資本和德福資本均以醫療健康領域為其重要投資方向,是極具專業投資能力和行業影響力的國際長期價值投資者。

那麼,醫療器械賽道是否有望復刻過去幾年創新藥之路?

本期格隆匯線下調研系列活動我們將組織大家深度調研高端精密醫療器械賽道的優質上市公司——先健科技(1302.HK)

【線下調研邀請】Tenbagger系列調研之先健科技(01302.HK)

出席嘉賓

董事局主席兼首席執行官:謝粵輝

投資者關係總監:餘佳慧

投資者關係:馬璐璐

形式

上市公司線下小範圍調研交流

時間

2020/11/26(週四) 15:30-17:30

地點

深圳(詳細地址報名成功後通知

報名對象

機構投資者

歡迎感興趣的機構投資者報名,報名需提供名片審核,本次調研限20人,需提前報名謝絕空降。

先健科技成立於1999年,始終專注於自主創新研發,歷經二十餘載的發展與沉澱,已實現完善的獨立自主知識產權體系和領先的技術創新能力,成為業內領先的心腦血管和外周血管微創介入醫療器械企業。先健科技兼具中國深度和國際化佈局,擁有一系列高水平的科研資質和科研配套,現已在全球範圍內實現超過1000項專利佈局。公司在結構性心臟病、外周血管病、心臟節律管理、腫瘤、心肺和神經領域均具有全面的創新產品佈局,並擁有全球首創的鐵基可吸收生物材料平台,在多個細分領域實現從無到有的技術突破。先健科技以高質量的微創介入醫療器械產品,給全球100多個國家和地區的醫生和患者帶來了安全有效的介入治療方案。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account